## CRYSTAL STRUCTURE OF *TRYPANOSOMA CRUZI* DIHYDROOROTATE DEHYDROGENASE <u>Pinheiro, M.P.<sup>1</sup></u>, Iulek, J.<sup>2</sup>, Nonato, M.C.<sup>1</sup>

<sup>1</sup>Laboratório de Cristalografia de Proteínas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, USP, Ribeirão Preto, SP, Brazil;
<sup>2</sup>Departamento de Química, UEPG, Ponta Grossa, PR, Brazil.

Dihydroorotate dehydrogenase (DHODH) catalyzes the oxidation of dihydroorotate to orotate, the first aromatic intermediate in the biosynthetic pathway toward pyrimidine nucleotides. At present, there is a great interest in inhibitors of DHODH as therapeutic agents for the treatment of cancer, rheumatoid arthrits and parasitic diasease. Trypanosoma cruzi is a protozoan parasite responsible for Chagas' Disease that according to the World Health Organization affects 16 to 18 million people in latin america and causes around 21.000 deaths a year. Here we present the crystallization and X-ray structure of *Tc*DHODH. Crystals of the *Tc*DHODH in fusion with 6xHis tag at the N-terminal were grown at 25°C by the hanging drop vapour-diffusion technique using ammonium sulfate as a precipitant. Crystals of *Tc*DHODH have been cryofrozen in presence of glycerol and synchrotron radiation data were colleted at the MX-1 beam line (LNLS). TcDHODH crystals belong to the orthorhombic space group  $P2_12_12_1$ , with unit-cell parameters a=82.39, b=123.92, c=128.89Å. The crystal structure of TcDHODH has been solved by molecular replacement and refined to 2.2Å resolution with 4 molecules in A.U. The three-dimensional structure of *Tc*DHODH can further be used for the design of highly specific inhibitors of *Tc*DHDOH through the technology of structure-based drug design as a tool against Chagas' Disease.

This work was fully supported by FAPESP.